- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02248389
Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses (HIFU-KIDNEY)
March 21, 2019 updated by: Chandru Sundaram, Indiana University
The Sonatherm device provides both advanced imaging (ultrasound guidance) and high intensity focused ultrasound to target and ablate tumors.
It also does not require piercing the tumor with a needle as does cryotherapy (Cryo) and radiofrequency (RF) ablation.
Cryo and RF also have high retreatment rates due the finding of untreated tumor on follow-up imaging.
Thus, there is reason to hypothesize that Sonatherm with it's real-time ultrasound imaging feedback could replace RF and Cryo for the treatment of small renal masses where the invasiveness of full resection partial nephrectomy is contraindicated due to patient comorbidities.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study uses a treat and resect model where ablation is followed by a partial nephrectomy.
This will allow for the ablation to be evaluated for necrosis and targeting accuracy.
It will also ensure cancer safety prior validation of the HIFU device.
The applied heat of HIFU ablation could improve hemostasis and blood loss.
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- IU Health University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥ 18 years of age.
- Must provide written informed consent
- Must have presence of an enhancing solid renal mass ≤ 3.0 cm on CT or MRI
- Must be scheduled for laparoscopic robot assisted partial nephrectomy of renal mass.
- Must have an expected survival status of at least 3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
- Previous chemotherapy, and/or biological therapy for cancer are permitted. The subject should have recovered from the effects of these or of any prior surgery.
- Women of child bearing potential must have negative pregnancy test (urine or serum) prior to study enrollment. Females must agree to adequate birth control if conception is possible during the study.
- All toxicities from prior therapy must be recovered to a grade 1 or better according to the Clavien-Dindo Classification system.
- If previous biopsy of mass has been done, pathology must be consistent with renal cell carcinoma (RCC).
Exclusion Criteria
- < 90% solid component of the tumor on screening cross-sectional imaging (CT/MRI)
- Prior ablative or surgical treatment of the lesion
- Masses located close to the hilar vessels or at locations that cannot be accessed with the HIFU probe
- The patient has only one kidney
- Multiple or bilateral renal masses
Failure to meet the following laboratory levels on preoperative screening:
- Platelet count ≥ 100,000 mm3
- Hemoglobin ≥ 10 g/dl.
- Prothrombin Time (PT) ≤ 1.5 times upper limit of laboratory normal (ULN).
- Activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN.
- Serum creatinine < 2.5 times ULN.
- Hepatic toxicity grade 2 (using CTCAE version 4 standard definitions)
- Inability to hold anticoagulation for surgery due to high risk of a cerebral vascular event, myocardial event, or like risk (ASA may be continued)
- Abdominal obesity that would, in the assessment of the PI, make the HIFU ablation difficult
- Participation in another investigational trial concurrently or within 30 days prior to enrollment
- Subjects with a diagnosis of metastatic disease who are currently receiving treatment or who are not in remission
Significant acute or chronic medical, neurologic, or psychiatric illness in the subject that, in the judgment of the Principal Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ablation arm
Each person in study will receive ablation of their renal tumor followed by standard partial nephrectomy.
|
HIFU ablation of tumor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operative and postoperative complications
Time Frame: 4-months
|
Observing complications as defined by the Clavien system (1-5).
|
4-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Necrosis
Time Frame: 1-week
|
A microscopic analysis will be performed to assess necrosis within the ablation zone.
|
1-week
|
Tumor targeting
Time Frame: 1-week
|
The ablation border beyond the tumor will be measured on pathologic analysis with success being defined as 1-10mm.
|
1-week
|
Surgeon rated ease of use
Time Frame: 1-week
|
A questionnaire assessing the ease of use of the Sonatherm instrument will be given to the surgeon after each case.
|
1-week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 4, 2014
Primary Completion (Actual)
June 8, 2015
Study Completion (Actual)
June 8, 2015
Study Registration Dates
First Submitted
September 19, 2014
First Submitted That Met QC Criteria
September 22, 2014
First Posted (Estimate)
September 25, 2014
Study Record Updates
Last Update Posted (Actual)
March 25, 2019
Last Update Submitted That Met QC Criteria
March 21, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IUCRO-0474
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Renal Cell
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
Osel, Inc.National Cancer Institute (NCI); City of Hope Medical Center; Miyarisan Pharmaceuticals...RecruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...United States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
Clinical Trials on Sonatherm 600i ablation system
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnRenal Carcinoma | Renal MassUnited States
-
Covidien, GI SolutionsCompletedESOPHAGEAL SQUAMOUS CELL CARCINOMAChina
-
Pentax MedicalCompletedEsophageal CancerUnited States
-
Medtronic - MITGCompletedHIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-Grade Squamous Intraepithelial LesionsUnited States
-
Medtronic CardiovascularCompletedAtrial FibrillationUnited States
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Abbott Medical DevicesTerminated
-
Thermedical, Inc.CompletedTachycardia, VentricularCanada
-
Medtronic CardiovascularCompleted